ASCO24: J&J reports four patient deaths in early-stage radiotherapy prostate cancer trial
Johnson & Johnson’s radiopharma candidate JNJ-6420 returned mixed results in an early-stage study, demonstrating strong biochemical and radiographic response but also resulting in four patient deaths.